EVENITY (romosozumab) is a prescription medication used to treat osteoporosis in postmenopausal women who are at high risk of bone fracture. It is a monoclonal antibody that works by inhibiting the activity of sclerostin, a protein involved in bone metabolism. By blocking sclerostin, EVENITY helps to increase bone formation and decrease bone resorption, which can lead to an increase in bone mineral density and a reduction in the risk of fracture. EVENITY is administered through subcutaneous injection and is typically prescribed when other osteoporosis treatments have not been effective or are not suitable. Due to its mechanism of action and its effects on bone turnover, the use of EVENITY is subject to specific treatment durations and considerations to ensure patient safety and efficacy.